Upregulation of Igf and Wnt signalling associated genes in pleomorphic adenomas of the salivary glands in PLAG1 transgenic mice

International Journal of Oncology

Volumn 32, Issue 5, 2008, Pages 1041-1047

  Declercq, Jeroen ^a   Van Dyck, Frederik ^a   Van Damme, Boudewijn ^a   Van De Ven, Wim J M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Insulin like growth factor 2; PLAG1 proto oncogene; Pleomorphic adenomas of the salivary glands; Transgenic mouse strains; Wnt signalling associated genes

Indexed keywords

BETA CATENIN; CRE RECOMBINASE; CYCLIN D1; GENE PRODUCT; PROTEIN DLK1; PROTEIN GTL2; PROTEIN H19; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; TUMOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; DNA BINDING PROTEIN; IGF2 PROTEIN, MOUSE; PLAG1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INACTIVATION; GENE TARGETING; GENETIC ASSOCIATION; MOUSE; NONHUMAN; PLEOMORPHIC ADENOMA; PLEOMORPHIC ADENOMA GENE 1; PRIORITY JOURNAL; SALIVARY GLAND TUMOR; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; CELL TRANSFORMATION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; TIME;

ADENOMA, PLEOMORPHIC; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; INSULIN-LIKE GROWTH FACTOR II; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SALIVARY GLAND NEOPLASMS; SIGNAL TRANSDUCTION; TIME FACTORS; WNT PROTEINS;

EID: 45849104632     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.5.1041     Document Type: Article

References (49)

1. Speight PM and Barrett AW: Salivary gland tumours. Oral Dis 8: 229-240, 2002.
2. Silvers AR and Som PM: Salivary glands. Radiol Clin North Am 36: 941-966, 1998.
3. Lee KC, Chan JK and Chong YW: Ossifying pleomorphic adenoma of the maxillary antrum. J Laryngol Otol 106: 50-52, 1992.
4. Olsen KS and Lewis JE: Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head Neck 23: 705-712, 2001.
5. Mizui T, Ishimaru JI, Miyamoto K and Toida M: Malignant transformation of a gigantic pleomorphic adenoma of the submandibular gland: a case report. J Oral Maxillofac Surg 58: 1422-1424, 2000.
6. Roijer E, Nordkvist A, Strom A-K, Ryd W, Behrendt M, Bullerdiek J, Mark J and Stenman G: Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma. Am J Pathol 160: 433-440, 2002.
7. Sandros J, Stenman G and Mark J: Cytogenetic and molecular observations in human and experimental salivary gland tumors. Cancer Genet Cytogenet 44: 153-167, 1990.
8. Bullerdiek J, Raabe G, Bartnitzke S, Boschen C and Schloot W: Structural rearrangements of chromosome Nh 8 involving 8q12: a primary event in pleomorphic ademona of the parotid gland. Genetica 72: 85-92, 1987.
9. Stenman G: Fusion oncogenes and tumor type specificity: insights from salivary gland tumors. Semin Cancer Biol 15: 224-235, 2005.
10. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H and Van de Ven WJ: Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10: 436-444, 1995.
11. Kas K, Voz ML, Roijer E, Astrom AK, Meyen E, Stenman G and Van de Ven WJ: Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet 15: 170-174, 1997.
12. Hensen K, Braem C, Declercq J, Van Dyck F, Dewerchin M, Fiette L, Denef C and Van de Ven WJ: Targeted disruption of the murine Plag1 proto-oncogene causes growth retardation and reduced fertility. Dev Growth Differ 46: 459-470, 2004.
13. Voz ML, Astrom AK, Kas K, Mark J, Stenman G and Van de Ven WJ: The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under control of the LIFR promoter. Oncogene 16: 1409-1416, 1998.
14. Astrom AK, Voz ML, Kas K, Roijer E, Wedell B, Mandahl N, Van de Ven W, Mark J and Stenman G: Conserved mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: identification of SII as a new fusion partner gene. Cancer Res 59: 918-923, 1999.
15. Asp J, Persson F, Kost-Alimova M and Stenman G: CHCHD7-PLAG1 and TCEA1-PLAG1 gene fusions resulting from cryptic, intrachromosomal 8q rearrangements in pleomorphic salivary gland adenomas. Genes Chromosomes Cancer 45: 820-828, 2006.
16. Astrom A, D'Amore ES, Sainati L, Panarello C, Morerio C, Mark J and Stenman G: Evidence of involvement of the PLAG1 gene in lipoblastomas. Int J Oncol 16: 1107-1110, 2000.
17. Hibbard MK, Kozakewich HP, Dal Cin P, Sciot R, Tan X, Xiao S and Fletcher JA: PLAG1 fusion oncogenes in lipoblastoma. Cancer Res 60: 4869-4872, 2000.
18. Morerio C, Rapella A, Rosanda C, Tassano E, Gambini C, Romagnoli G and Panarello C: PLAG1-HAS2 fusion in lipoblastoma with masked 8q intrachromosomal rearrangement. Cancer Genet Cytogenet 156: 183-184, 2005.
19. Zatkova A, Rouillard JM, Hartmann W, Lamb BJ, Kuick R, Eckart M, von Schweinitz D, Koch A, Fonatsch C, Pietsch T, Hanash SM and Wimmer K: Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer 39: 126-137, 2004.
20. Castilla LH, Perrat P, Martinez NJ, Landrette SF, Keys R, Oikemus S, Flanegan J, Heilman S, Garrett L, Dutra A, Anderson S, Pihan GA, Wolff L and Liu PP: Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc Natl Acad Sci USA 101: 4924-4929, 2004.
21. Landrette SF, Kuo YH, Hensen K, Barjesteh van Waalwijk van Doom-Khosrovani S, Perrat PN, Van de Ven WJ, Delwel R and Castilla LH: Plag1 and Plag12 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11. Blood 105: 2900-2907, 2005.
22. Hensen K, Van Valckenborgh IC, Kas K, Van de Ven WJ and Voz ML: The tumorigenic diversity of the three PLAG family members is associated with different DNA binding capacities. Cancer Res 62: 1510-1517, 2002.
23. Declercq J, Van Dyck F, Braem CV, Van Valckenborgh IC, Voz M, Wassef M, Schoonjans L, Van Damme B, Fiette L and Van de Ven WJ: Salivary gland tumors in transgenic mice with targeted PLAG1 proto-oncogene overexpression. Cancer Res 65: 4544-4553, 2005.
24. Zhao X, Ren W, Yang W, Wang Y, Kong H, Wang L, Yan L, Xu G, Fei J, Fu J, Zhang C and Wang Z: Wnt pathway is involved in pleomorphic adenomas induced by overexpression of PLAG1 in transgenic mice. Int J Cancer 118: 643-648, 2006.
25. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R and Hennighausen L: Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 10: 545-553, 2001.
26. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA and Hennighausen L: Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 25: 4323-4330, 1997.
27. Voz ML, Mathys J, Hensen K, Pendeville H, Van Valckenborgh I, Van Huffel C, Chavez M, Van Damme B, De Moor B, Moreau Y and Van de Ven WJ: Microarray screening for target genes of the proto-oncogene PLAG1. Oncogene 23: 179-191, 2004.
28. Voz ML, Agten NS, Van de Ven WJ and Kas K: PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res 60: 106-113, 2000.
29. DeChiara TM, Efstratiadis A and Robertson EJ: A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345: 78-80, 1990.
30. DeChiara TM, Robertson EJ and Efstratiadis A: Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64: 849-859, 1991.
31. Sachdev D and Yee D: The IGF system and breast cancer. Endocr Relat Cancer 8: 197-209, 2001.
32. Helle SI: The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab 18: 67-79, 2004.
33. Hadsell DL and Bonnette SG: IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia 5: 19-30, 2000.
34. Tricoli JV, Rall LB, Karakousis CP, Herrera L, Petrelli NJ, Bell GI and Shows TB: Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 46: 6169-6173, 1986.
35. Martin DC, Fowlkes JL, Babic Band Khokha R: Insulin-like growth factor II signalling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol 146: 881-892, 1999.
36. van Noort M, Meeldijk J, van der Zee R, Destree O and Clevers H: Wnt signalling controls the phosphorylation status of beta-catenin. J Biol Chem 277: 17901-17905, 2002.
37. Werner H and Le Roith D: The insulin-like growth factor-I receptor signalling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 8: 71-92, 1997.
38. Bates P, Fisher R, Ward A, Richardson L, Hill DJ and Graham CF: Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 72: 1189-1193, 1995.
39. Pravtcheva DD and Wise TL: Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J Exp Zool 281: 43-57, 1998.
40. Van Den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng C-N, Mcdermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB and Yee D: polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer 33: 1108-1113, 1997.
41. Miyamoto S, Nakamura M, Shitara K, Nakamura K, Ohki Y, Ishii G, Goya M, Kodama K, Sangai T, Maeda H, Shi-Chuang Z, Chiba T and Ochiai A: Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res 11: 3494-3502, 2005.
42. Goya M, Miyamoto S, Nagai K, Ohki Y, Nakamura K, Shitara K, Maeda H, Sangai T, Kodama K, Endoh Y, Ishii G, Hasebe T, Yonou H, Hatano T, Ogawa Y and Ochiai A: Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 64: 6252-6258, 2004.
43. Yee D: Targeting insulin-like growth factor pathways. Br J Cancer 94: 465-468, 2006.
44. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS and Yee D: A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63: 627-635, 2003.
45. Wang Y, Hailey J, Williams D, Lipari P, Malkowski M, Wang X, Xie L, Li G, Saha D, Ling WL, Cannon-Carlson S, Greenberg R, Ramos RA, Shields R, Presta L, Brams P, Bishop WR and Pachter JA: Inhibition of insulin-like growth factor-I receptor (IGF-IR) signalling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 4: 1214-1221, 2005.
46. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M and Erlichman C: In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66: 362-371, 2006.
47. Wittman M, Carboni J, Attar R, Balasubramanian B, Balimane P, Brassil P, Beaulieu F, Chang C, Clarke W, Dell J, Eummer J, Frennesson D, Gottardis M, Greer A, Hansel S, Hurlburt W, Jacobson B, Krishnananthan S, Lee FY, Li A, Lin TA, Liu P, Ouellet C, Sang X, Saulnier MG, Stoffan K, Sun Y, Velaparthi U, Wong H, Yang Z, Zimmermann K, Zoeckler M and Vyas D: Discovery of a (1H-benzoimidazol-2-yl) 1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem 48: 5639-5643, 2005.
48. Thomas GV: mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 16: 78-84, 2006.
49. Queimado L, Lopes CS and Reis AM: WIF1, an inhibitor of the Wnt pathway, is rearranged in salivary gland tumors. Genes Chromosomes Cancer 46: 215-225, 2007.